These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 20200517)

  • 21. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.
    Ozer N; Cam N; Tangurek B; Ozer S; Uyarel H; Oz D; Guney MR; Ciloglu F
    Heart Vessels; 2010 Mar; 25(2):155-62. PubMed ID: 20339978
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Integrated analysis of genetic variation and gene expression reveals novel variant for increased warfarin dose requirement in African Americans.
    Hernandez W; Gamazon ER; Aquino-Michaels K; Smithberger E; O'Brien TJ; Harralson AF; Tuck M; Barbour A; Cavallari LH; Perera MA
    J Thromb Haemost; 2017 Apr; 15(4):735-743. PubMed ID: 28135054
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9.
    Tham LS; Goh BC; Nafziger A; Guo JY; Wang LZ; Soong R; Lee SC
    Clin Pharmacol Ther; 2006 Oct; 80(4):346-55. PubMed ID: 17015052
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of common and rare genetic variation on warfarin dose among African-Americans and European-Americans using the exome array.
    Liu N; Irvin MR; Zhi D; Patki A; Beasley TM; Nickerson DA; Hill CE; Chen J; Kimmel SE; Limdi NA
    Pharmacogenomics; 2017 Jul; 18(11):1059-1073. PubMed ID: 28686080
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Implications of Polymorphisms in the BCKDK and GATA-4 Gene Regions on Stable Warfarin Dose in African Americans.
    Bargal SA; Kight JN; Augusto de Oliveira F; Shahin MH; Langaee T; Gong Y; Hamadeh IS; Cooper-DeHoff RM; Cavallari LH
    Clin Transl Sci; 2021 Mar; 14(2):492-496. PubMed ID: 33278335
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.
    Kimura R; Miyashita K; Kokubo Y; Akaiwa Y; Otsubo R; Nagatsuka K; Otsuki T; Okayama A; Minematsu K; Naritomi H; Honda S; Tomoike H; Miyata T
    Thromb Res; 2007; 120(2):181-6. PubMed ID: 17049586
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The future of warfarin pharmacogenetics in under-represented minority groups.
    Cavallari LH; Perera MA
    Future Cardiol; 2012 Jul; 8(4):563-76. PubMed ID: 22871196
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
    Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
    J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
    [TBL] [Abstract][Full Text] [Related]  

  • 29. VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients.
    Oner Ozgon G; Langaee TY; Feng H; Buyru N; Ulutin T; Hatemi AC; Siva A; Saip S; Johnson JA
    Eur J Clin Pharmacol; 2008 Sep; 64(9):889-94. PubMed ID: 18542936
    [TBL] [Abstract][Full Text] [Related]  

  • 30. VKORC1 V66M mutation in African Brazilian patients resistant to oral anticoagulant therapy.
    Orsi FA; Annichino Bizzacchi JM; de Paula EV; Ozelo MC; Langley MR; Weck KE
    Thromb Res; 2010 Sep; 126(3):e206-10. PubMed ID: 20615525
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans.
    Kimmel SE; Christie J; Kealey C; Chen Z; Price M; Thorn CF; Brensinger CM; Newcomb CW; Whitehead AS
    Pharmacogenomics J; 2008 Feb; 8(1):53-60. PubMed ID: 17325732
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of CYP2C9 and VKORC1 genetic polymorphisms upon warfarin dose requirements in Egyptian patients with acute coronary syndrome.
    Ghozlan MF; Foad DA; Darwish YW; Saad AA
    Blood Coagul Fibrinolysis; 2015 Jul; 26(5):499-504. PubMed ID: 25699611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of VKORC1 and CYP2C9 gene polymorphisms in Indian population and its effect on warfarin response.
    Shalia KK; Doshi SM; Parikh S; Pawar PP; Divekar SS; Varma SP; Mehta R; Doctor T; Shah VK; Saranath D
    J Assoc Physicians India; 2012 Dec; 60():34-8. PubMed ID: 23781667
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations.
    Wu AH; Wang P; Smith A; Haller C; Drake K; Linder M; Valdes R
    Pharmacogenomics; 2008 Feb; 9(2):169-78. PubMed ID: 18370846
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Race influences warfarin dose changes associated with genetic factors.
    Limdi NA; Brown TM; Yan Q; Thigpen JL; Shendre A; Liu N; Hill CE; Arnett DK; Beasley TM
    Blood; 2015 Jul; 126(4):539-45. PubMed ID: 26024874
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacogenetics of oral anticoagulants: a basis for dose individualization.
    Stehle S; Kirchheiner J; Lazar A; Fuhr U
    Clin Pharmacokinet; 2008; 47(9):565-94. PubMed ID: 18698879
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Warfarin sensitivity genotyping: a review of the literature and summary of patient experience.
    Moyer TP; O'Kane DJ; Baudhuin LM; Wiley CL; Fortini A; Fisher PK; Dupras DM; Chaudhry R; Thapa P; Zinsmeister AR; Heit JA
    Mayo Clin Proc; 2009 Dec; 84(12):1079-94. PubMed ID: 19955245
    [TBL] [Abstract][Full Text] [Related]  

  • 38. VKORC1 -1639G>A and CYP2C9*3 are the major genetic predictors of phenprocoumon dose requirement.
    Puehringer H; Loreth RM; Klose G; Schreyer B; Krugluger W; Schneider B; Oberkanins C
    Eur J Clin Pharmacol; 2010 Jun; 66(6):591-8. PubMed ID: 20376629
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Copy number variation and warfarin dosing: evaluation of CYP2C9, VKORC1, CYP4F2, GGCX and CALU.
    Scott SA; Patel M; Martis S; Lubitz SA; van der Zee S; Yoo C; Edelmann L; Halperin JL; Desnick RJ
    Pharmacogenomics; 2012 Feb; 13(3):297-307. PubMed ID: 22188360
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population.
    Veenstra DL; You JH; Rieder MJ; Farin FM; Wilkerson HW; Blough DK; Cheng G; Rettie AE
    Pharmacogenet Genomics; 2005 Oct; 15(10):687-91. PubMed ID: 16141794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.